Business
MSYS jointly publishes bioprocessing data with MIT
MSYS jointly publishes bioprocessing data with MIT.
About this update from Metir Plc
[{"type":"text","content":"\n \nRNS Number : 7967R Microsaic Systems plc 05 March 2019 \n\n5 March 2019\nMicrosaic Systems plc\n(\"Microsaic\" or the \"Company\")\n \nMicrosaic jointly publishes bioprocessing data with MIT\n \nMicrosaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry (\"MS\") instruments, announces its joint publication with Massachusetts Institute of Technology (\"MIT\") \"Using MS for point of need bioprocessing\".\n \nToday, Microsaic and MIT will be showcasing the latest results of their collaboration in advancing point of need bioprocessing analysis, at the International Foundation of Process Analytical Chemistry (\"IFPAC\") 2019, in Washington, DC.\nThis latest phase in the collaboration looks at the effects of storage and time conditions, feeding strategies, and media type on protein quality, and compares frozen and fresh cell cultures. The new demands of modern bioprocessing (for the manufacture of biologic drugs, or \"biologics\") together with the implementation of Quality by Design (\"QbD\") and Process Analytical Technology (\"PAT\") methods require a deeper understanding of these processes. MS is well placed to provide the information rich data required.\nGlenn Tracey, CEO of Microsaic, commented, \"Traditional mass spectrometers are large, expensive, and require operation by specialists in centralised laboratories. Integrated real-time MS, decentralized and at the point-of-need, could provide important process information quickly and at a reduced cost. Microsaic is working closely with MIT, at the feasibility of using deployable and compact mass spectrometry for the direct analysis of upstream cell cultures to show a compelling user scenario for our technology.\"\n \nBiologic drugs represented eight out of ten top selling drugs in 2017, and estimated revenues will reach over $380Bn by 2024. The Directors believe that the total market for bioprocessing equipment in the pharmaceutical industry is currently in the region of $15Bn. \n \nRecently, Microsaic announced its innovative new product, the MiD® ProteinID, which the Analytical Scientist recognised as one of the top innovative products of 2018. \n \n\n\n\nEnquiries:\n \n\n\n \n\n\n\n\nMicrosaic Systems plc\nGlenn Tracey, CEO\nBevan Metcalf, FD\n\n\n+44 (0) 1483 751 577\n\n\n\n\n \nN+1 Singer (Nomi...